Among the parameters that may assist in selecting target disease for CXCL10 or CXCL9 based therapies are results of pre-clinical trials in experimental models of various cancer diseases, and selection based on human data from cancer patients regarding the association of CXCL10/CXCL9 expression at the tumor site, or sera levels of these chemokines, and cancer prognosis. This evidence concerns the gene CXCL9 and cancer.